OCUGEN, INC. Proceeds from Long-term Lines of Credit
OCUGEN, INC. (OCGN) reported Proceeds from Long-term Lines of Credit of $0 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2021-05-07
- OCUGEN, INC. proceeds from long-term lines of credit for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. proceeds from long-term lines of credit for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. proceeds from long-term lines of credit for the quarter ending 2020-06-30 was $421.42K, a 85.21% decline year-over-year.
- OCUGEN, INC. proceeds from long-term lines of credit for the quarter ending 2020-03-31 was $500.00K, a 65.52% decline year-over-year.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month |
|---|---|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $421.42K derived: sum of 2 quarters · filed 2020-11-06 | $921.41K 10-Q · filed 2020-11-06 |
| 2020-06-30 | $421.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $921.41K 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $500.00K 10-Q · filed 2021-05-07 | ||
| 2019-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $5.35M derived: sum of 2 quarters · filed 2020-11-06 | $6.80M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $4.30M 10-Q · filed 2020-08-14 | |
| 2019-03-31 | $1.45M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |